PMID- 31016378
OWN - NLM
STAT- In-Process
LR  - 20190610
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 34
IP  - 6
DP  - 2019 Jun
TI  - Preoperative serum carcinoembryonic antigen elevation in stage I colon cancer:
      improved risk of mortality in stage T1 than in stage T2.
PG  - 1095-1104
LID - 10.1007/s00384-019-03298-y [doi]
AB  - PURPOSE: This study aimed to investigate the implications of preoperative serum
      carcinoembryonic antigen (CEA) elevation in cause-specific survival (CSS) of
      patients diagnosed with stage I (T1N0M0 and T2N0M0) colon cancer. METHODS:
      Eligible patients diagnosed with stage I colon cancer from the Surveillance,
      Epidemiology, and End Results (SEER) database from January 2004 to December 2010 
      were included in this respective and propensity score-matched (PSM) study. Some
      Cox proportional hazards models were constructed to identify prognostic factors
      associated with oncologic outcomes of colon cancer. Pearson's chi-squared tests
      and Kaplan-Meier methods were performed. RESULTS: The median follow-up time of
      the whole cohort was 79 months. A total of 16,659 patients diagnosed with stage I
      colon cancer were identified from the SEER database. Multivariate Cox analyses
      showed that stage T1N0M0 in the context of serum CEA elevation (T1, CEA+)
      presented up to 158.4% increased risk of colon cancer-specific mortality compared
      with stage T1N0M0 in the context of normal serum CEA [hazard ratio (HR) = 2.584, 
      95% confidence interval (CI) = 2.167-3.082, P < 0.001]. After PSM, Kaplan-Meier
      survival curves of stage T1N0M0 colon cancer showed that 5-year CSS rates of
      normal and elevated CEA were 94.8% and 96.6% (P < 0.001). CONCLUSIONS: This large
      population-based and propensity score-matched study with long follow-up time
      provides the first evidence that stage T1N0M0 colon cancer with the elevation of 
      preoperative serum CEA would be a surrogate of aggressive tumor biology and
      predict poor prognosis. In addition, this subgroup of colon cancer might need to 
      be paid more attention of clinicians.
FAU - Shen, Feng
AU  - Shen F
AD  - Department of Colorectal Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui
      Road, Hangzhou, 310012, Zhejiang, China.
FAU - Cui, Junhui
AU  - Cui J
AD  - Department of Colorectal Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui
      Road, Hangzhou, 310012, Zhejiang, China.
FAU - Hong, Xia
AU  - Hong X
AD  - Department of Colorectal Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui
      Road, Hangzhou, 310012, Zhejiang, China.
FAU - Yu, Feng
AU  - Yu F
AD  - Department of Colorectal Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui
      Road, Hangzhou, 310012, Zhejiang, China.
FAU - Bao, Xiangdong
AU  - Bao X
AD  - Department of Colorectal Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui
      Road, Hangzhou, 310012, Zhejiang, China. sfload78@sohu.com.
LA  - eng
PT  - Journal Article
DEP - 20190423
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
OTO - NOTNLM
OT  - Carcinoembryonic antigen
OT  - Colon cancer
OT  - Propensity score-matched
OT  - Stage I
EDAT- 2019/04/25 06:00
MHDA- 2019/04/25 06:00
CRDT- 2019/04/25 06:00
PHST- 2019/04/10 00:00 [accepted]
PHST- 2019/04/25 06:00 [pubmed]
PHST- 2019/04/25 06:00 [medline]
PHST- 2019/04/25 06:00 [entrez]
AID - 10.1007/s00384-019-03298-y [doi]
AID - 10.1007/s00384-019-03298-y [pii]
PST - ppublish
SO  - Int J Colorectal Dis. 2019 Jun;34(6):1095-1104. doi: 10.1007/s00384-019-03298-y. 
      Epub 2019 Apr 23.